Scientists create CRISPR-based drug candidate targeting the microbiome

A new drug candidate targeting E. coli in the gut is in phase 1 clinical trials. According to a new paper it may improve the well-being of blood cancer patients and reduce their mortality rate from E. coli infections.

from Latest Science News -- ScienceDaily https://ift.tt/qJmEtRr

Comments

Popular posts from this blog

Seismic study reveals key reason why Patagonia is rising as glaciers melt

New method to detect and visualize sperm cells recovered from forensic evidence